TrimRx's Blog

Tirzepatide reduces systolic blood pressure by 5–8 mmHg on average — here’s the mechanism, timeline, and what happens when you stop the medication.

Tirzepatide reduces systemic inflammation through GLP-1 and GIP receptor activation, improving metabolic markers beyond weight loss alone.

Tirzepatide carries no elevated cancer risk in human trials. Animal studies found thyroid tumors at extreme doses — context matters. Full evidence

Tirzepatide reduces obstructive sleep apnea severity through weight loss and direct airway effects — clinical trials show 25–55% reduction in AHI scores

Tirzepatide demonstrates 59% NASH resolution in clinical trials — significantly outperforming placebo. Evidence, mechanisms, and practical patient

Tirzepatide carries no black box warning. FDA mandates a thyroid tumor risk advisory instead. Here’s the regulatory reality and patient safety profile.

Tirzepatide carries a medullary thyroid cancer risk based on rodent studies—here’s what human research shows, who shouldn’t take it, and how to assess

Tirzepatide 5mg is the first maintenance dose after titration, typically reached at week 4. Here’s what happens at this level and what results to expect.

The 15mg tirzepatide dose achieves 20.9% mean weight reduction but requires 20-week titration — here’s what patients starting GLP-1 therapy need to know.